GlassScriptPhysician profile
Joyce J Huang
NPI 1285991638
$28,839.90
in general payments reported to CMS, 2019-2025
39 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $3,846 · 2021: $2,570 · 2022: $5,197 · 2023: $12K · 2024: $4,887 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $1,092 · Travel and Lodging: $717 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,945.00 |
| Food and Beverage | $1,091.56 |
| Travel and Lodging | $717.03 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $10,205.66 | 2023 | |
| Abbvie INC. | $6,857.05 | 2020-2025 | |
| Janssen Biotech, INC. | $2,882.75 | 2019-2024 | Carvykti |
| Eisai INC. | $2,358.00 | 2020 | |
| Beigene USA, INC. | $1,422.02 | 2021-2024 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $1,023.18 | 2022-2023 | Fotivda |
| Gilead Sciences, INC. | $1,011.92 | 2021 | |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $447.76 | 2020-2025 | Enhertu, Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $282.12 | 2019-2022 | |
| Celgene Corporation | $185.09 | 2020-2023 | Reblozyl |
| Epizyme, INC. | $158.67 | 2020-2021 | |
| Astellas Pharma US INC | $143.76 | 2023-2025 | Xospata, Vyloy |
| Genentech USA, INC. | $106.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $84.75 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.